ÂÜÀòÂÒÂ×

Emilie Gauthy has been working in the biotechnology industry since 2008. Emilie began their career as a Research Fellow in Immunology at the de Duve Institute in 2008, where they managed projects in Cancer Immunology with the goal of discovering therapeutic targets to improve human immune responses. Emilie then moved on to Quality Assistance as a QC Scientist in 2014, followed by GSK as a QA Supervisor Clinical Manufacturing, Quality for Research & Developement. In 2017, they became a Project Manager at Cenexi LT, managing CMC and life cycle projects of sterile drug products. In 2018, they joined Celyad Oncology as the Development & Validation Director, where they led the team involved in Development and Validation of Celyad Oncology’s CAR-T cells candidate products. Emilie later held the roles of Senior Manager Development & Validation and R&D Manager CMC and Process Development. In 2022, they began their current role as Head of CMC at Zelluna Immunotherapy.

Emilie Gauthy's education history includes a Master in Management (D.E.S) from Ichec Brussels Management School between 2012 and 2014, a PhD in Biomedical and Pharmaceutical Sciences from Université catholique de Louvain between 2008 and 2013, a MSc in Bio-engineering from Université catholique de Louvain between 2003 and 2008, an Erasmus Exchange Program from University of Aberdeen since 2007, and high school from Lycée Martin V between 1997 and 2003.